The Impact on the Therapeutic Decision of Massive Gene Sequencing (NGS) in Plasma from Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy based on NGS represents a reliable and minimally invasive approach for the genomic characterization of advanced NSCLC. In this real-world cohort, ctDNA profiling enabled the identification of actionable alterations in a relevant proportion of patients, supporting its integration into routine clinical practice for therapeutic decision-making.
Authors
- Ana Blasco (ORCID: https://orcid.org/0000-0001-5889-0382)
- J. Garde (ORCID: https://orcid.org/0000-0001-7043-067X)
- Antonio Llombart‐Cussac (ORCID: https://orcid.org/0000-0003-4515-8293)
- José Vidal-Martínez (ORCID: https://orcid.org/0000-0002-5986-7966)
- Sonia Maciá-Escalante
- María Leonor Fernández-Murga (ORCID: https://orcid.org/0000-0001-7123-9834)
- José García-Sánchez (ORCID: https://orcid.org/0000-0003-0642-9118)
- Paula Llor-Rodriguez
Institutions
- University of Alicante (ES)
- Universidad Cardenal Herrera CEU (ES)
- Clínica IVI Alicante (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (ES)
- Fundación Instituto Valenciano de Oncología (ES)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3390/cancers17213469
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00